FDA & Government News

FDA Warns of Topical Finasteride Risks

The FDA has issued a safety alert on compounded topical finasteride products, citing adverse events and emphasizing the lack of regulatory approval or safety evaluation.

Share

5 Key Takeaways

  • 1

    Compounded topical finasteride products lack FDA approval.

  • 2

    Adverse effects include sexual dysfunction and mood disturbances.

  • 3

    Risks persist even after discontinuation.

  • 4

    Potential risks should be discussed with patients.

  • 5

    Healthcare professionals should report adverse events to the FDA MedWatch program.

Original Source(s)

FDA Warns of Topical Finasteride Risks

The FDA has issued a safety alert on compounded topical finasteride products, citing adverse events and emphasizing the lack of regulatory approval or safety evaluation.

  • by Kathryn Wighton

  • April 24, 2025

  • 2 min

Related Content

Patient Insights on HRQOL in Chronic GVHD

Explore how cutaneous graft-versus-host disease impacts patients’ quality of life across physical, psychological, and social domains.

Alopecia Areata Linked to Mental, Autoimmune Risks

Skin Pigmentation: Rethinking Drug Efficacy

With skin pigmentation influencing drug binding and potentially altering therapeutic outcomes, understanding melanin's role in pharmacokinetics is key to advancing equitable treatments.